Close menu

December 19th, 2022 | 13:57 CET

BioNTech top, Morphosys flop and Defence Therapeutics takeover candidate?

  • Biotechnology
  • vaccine
  • Cancer
Photo credits:

Biotech shares are volatile. Investors were reminded of this again just last week. Moderna shares initially rose by almost 30%, only to fall back by around 10% towards the weekend. But overall, the mood in the biotech segment was positive. Moderna reported positive study results on a combination therapy of a Moderna cancer vaccine and the tumor drug pembrolizumab from Merck & Co. At BioNTech, two buy recommendations and the expansion in Asia created a good mood. This mood has also prevailed at Defence Therapeutics for several weeks. The Canadians reported positive study results against tumors, and their Accum technology delivers what it promises, in which case mRNA specialists such as Moderna, BioNTech and Co. should be interested in a cooperation or even acquisition. In contrast, Morphosys slides to a new multi-year low.

time to read: 3 minutes | Author: Fabian Lorenz

Table of contents:

    BioNTech: Is the breakout on the way?

    While mRNA technology is not new, it is thanks to BioNTech and Moderna's COVID-19 vaccines based on it that it has gained widespread attention. However, this is said to be just the beginning. Market researchers at Precedence Research expect the market for mRNA therapeutics to grow by an average of 13% to more than USD 128 billion by 2030. German top dog BioNTech and competitor Moderna are focusing heavily on vaccines to fight cancer, among other things. In Germany alone, almost half a million people are diagnosed with cancer - every year. And the disease often ends fatally. In 2020, around 200,000 people in Germany died as a result. The figures illustrate how important a vaccine against the disease would be. The race for initial approval is on, and BioNTech is in the lead thanks to billions in profits from the COVID-19 vaccine. The pipeline currently includes 19 product candidates in 24 ongoing clinical trials. For 2023, BioNTech has announced new data from up to 10 clinical trials. Driven by hopes of positive newsflow and analyst commentary, the stock is currently on pace to break out of its 2022 sideways trend. The BioNTech share is currently trading at around EUR 186.

    Bank of America upgraded BioNTech from "Neutral" to "Buy" last week. The analysts' price target for the stock is USD 239. The experts at Bryan Garnier & Co are also confident that BioNTech will convince in the coming year. Their price target for the share of the Mainz-based mRNA specialists is USD 250.

    Defence Therapeutics: Takeover candidate thanks to a booster for mRNA vaccines?

    The Defence Therapeutics share has also moved a good distance away from its low for the year of EUR 1.03. However, at EUR 1.40, the share price of the Canadian biotech company is still well below the high for the year of around EUR 4. Two aces up the Company's sleeve speak in favor of further price increases. One of them could even make Defence Therapeutics an attractive takeover candidate for mRNA specialists such as Moderna and BioNTech.

    Defence Therapeutics is currently researching the combination of its patented Accum technology with mRNA vaccines. The Canadians believe Accum can increase the stability and potency of mRNA vaccines. The Defence team is therefore working with a European partner company to synthesize mRNA vaccines in conjunction with Accum. The goal is to directly compare Accum-linked and "pure" mRNA vaccines in terms of their potential to generate an immune response and eradicate existing tumors. If Accum becomes a booster for mRNA vaccines, mRNA specialists such as Moderna, BioNTech & Co. would have to be interested in collaborating with Defence Therapeutics - or someone would buy the entire company outright. After all, with a market capitalization of CAD 85 million, the Canadians are anything but expensive.

    In principle, the Accum method should enable more efficient and effective vaccines since vaccine antigens and antibody-drug conjugates are transported to the respective target cells in an intact form. The focus of the Canadians is on cancer and infectious diseases. The Company also conducts its own research on vaccines. Most recently, the successful completion of a GLP study in connection with the anti-cancer molecule AccuTOX was reported. The vaccine was shown to be highly effective in animals with no undesirable side effects. The active ingredient triggers oxidative stress in tumor cells, causing these tumor cells to die. Therefore, in coordination with the US Food and Drug Administration (FDA), the Phase 1 trial is expected to start as early as the first quarter of 2023.

    Morphosys: Price slide after Goldman recommendation

    Back again to the volatility of biotech stocks. Last Friday, Morphosys shareholders experienced the downward volatility of biotech stocks. Although the share recovered from its lows during the course of the day, it still lost over 10% and is now trading below EUR 13. The reason for the price slide on Friday: The share of the biotech company was downgraded by Goldman Sachs from "Neutral" to "Sell". The analysts halved the price target from EUR 24 to EUR 12. The current sales driver Monjuvi has yet to meet expectations. The drug pipeline is also sobering. Morphosys recently had to report failures with otilimab and gantenerumab. The share price is now at its lowest level since 2009, and no improvement seems to be in sight.

    After COVID-19, BioNTech and Moderna are now engaged in an exciting race for cancer vaccines. Those who like it more speculative should look at Defence Therapeutics. The recent newsflow is promising. Quite the opposite is true for Morphosys. A countermovement is possible at any time, but positive news is needed for a sustainable uptrend. This news is not in sight.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET

    Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech

    • Biotechnology
    • Pharma

    The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.


    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.


    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.